SEC Form 4 · accession 0001209191-19-018222
Tvardi Therapeutics, Inc. · TVRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederique Menzaghi Ph.D.
Officer — Chief Scientific Off,SVP-R&D
Period of report
Mar 6, 2019
Accepted (ET)
Mar 8, 2019 · 5:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346830
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $16.10 | Mar 6, 2019 | A | 150,000 | A | — | Mar 6, 2029 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 6, 2019, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.